Embargoed for 9am CET (3am ET) on Monday November 3rdAmgen Ventures-backed AAVantgarde Bio has raised $143 million in series B funding that the Italian biotech will use to | Amgen Ventures-backed ...

Roughly 70 to 80% of ovarian cancer cases are diagnosed at an advanced stage,1 where treatment options are limited and ...

Nanobiotix is continuing to find fresh ways to eke money out of its Johnson & Johnson-partnered, phase 3-stage cancer drug. | ...

Welcome to the Fierce Biotech Graveyard, a yearly ritual where we remember all the biotechs we lost in 2025. While we're ...

4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 ...

Thermo Fisher Scientific is breaking out the big bills to score a clinical research treat. With $8.875 billion in cash, the ...

Illumina’s revenue was flat for the third quarter as the sequencing giant continues to deal with headwinds from a China sales ...

Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

In parallel with mazisotine’s shelving, Lilly added a phase 1 NaV1.8 inhibitor from its SiteOne Therapeutics acquisition to ...

Secondary endpoints “indicate symptom reduction and patient benefit beyond improvement in disease activity,” according to ...

GSK once dreamed of harnessing the CD226 axis to create a new generation of blockbuster cancer drugs. | GSK once dreamed of ...

Bristol Myers Squibb is shedding two clinical programs, one from its 2023 Mirati buyout and another from a partnership with U ...